Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04191421 · ClinicalTrials.gov registry record · Phase 1
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT04191421 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 35 participants.
The verdict
NCT04191421, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies the best dose and side effects of siltuximab and how well it works in combination with spartalizumab in treating patients with pancreatic cancer that has spread to other places in the body. Monoclonal antibodies, such as siltuximab and spartalizumab, interfere with the ability of tumors cells to grow and spread.
Interventions
- BIOLOGICAL Siltuximab
- BIOLOGICAL Spartalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-01-17 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04191421
The ClinicalTrials.gov registry entry for NCT04191421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Siltuximab is the first listed.
NCT04191421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04191421 about?
NCT04191421 is a clinical study titled "Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer". This phase Ib/II trial studies the best dose and side effects of siltuximab and how well it works in combination with spartalizumab in treating patients with pancreatic cancer that has spread to other places in the body. Monoclonal antibodies, such as siltuximab and spartalizumab, interfere with the...
What is the current status of trial NCT04191421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2020-01-17. Estimated completion is 2023-04-05.
What interventions are being tested in trial NCT04191421?
The interventions under investigation include: Siltuximab (BIOLOGICAL), Spartalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04191421?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.